Advertisement

Prognostic Predictors: Genetic Signatures, Adjuvant!, and PREDICT

  • Marcelo Rocha Cruz
  • Antônio Carlos Buzaid
Chapter

Abstract

Predictive factors are responsible in determining the recurrence risk and death related to cancer and therefore to stablish the natural history of the disease regardless the treatment performed. Predictive factors are those that determine the outcome to a treatment.

Keywords

Genomic profile Oncotype DX Mammaprint Prognostic Prediction 

Recommended Reading

  1. 1.
    Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat. 2012;131(2):413–24. Algorithm based on pathological anatomy that suggests which patients do not need to undergo OncotypeDx analysis in the decision-making process.CrossRefGoogle Scholar
  2. 2.
    Cardoso F, van’t Veer LJ, Bogaerts J, et al. J 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–29. Results of the randomized study employing Mammaprint test.CrossRefGoogle Scholar
  3. 3.
    Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–98. European guideline encompassing the use of molecular signatures on initial breast cancer.CrossRefGoogle Scholar
  4. 4.
    Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:1134–50. ASCO’s guideline on the recommendations of molecular signatures. This publication was updated in 2017 after the publication of the MINDACT study.CrossRefGoogle Scholar
  5. 5.
    Krop I, Ismaila N, Andre F, Bast RC, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol. 2017. Atualização da diretriz da ASCO publicada em 2016, com foco nos resultados do estudo randomizado MINDACT, ampliando a recomendação do teste Mammaprint. ASCO’s updated guideline published in 2016, emphasizing the results of the randomized MINDACT study, extending the recommendation of the Mammaprint test.Google Scholar
  6. 6.
    Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005–14. Prospective analysis of the low risk group RS (<11) from the TAILORx study employing the Oncotype DX test.CrossRefGoogle Scholar
  7. 7.
    Wishart GC, Bajdik CD, Dicks E, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012;107(5):800–7. This study demonstrates the value of the PREDICT tool versus Adjuvant! and demonstrates that the PREDICT, incorporating the status of HER2, is more accurate.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Marcelo Rocha Cruz
    • 1
  • Antônio Carlos Buzaid
    • 2
  1. 1.Clinical OncologySírio-Libanês HospitalSão PauloBrazil
  2. 2.Clinical OncologyBP MiranteSão PauloBrazil

Personalised recommendations